How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?

Background and objective For advanced non-small cell lung cancer (NSCLC) patients who benefited from prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy, the choice of a second TKI therapy has gradually become a new strategy for the treatment. Some investigators recom...

Full description

Bibliographic Details
Main Authors: Chuanhao TANG, Xiaoyan LI, Wanfeng GUO, Jianjie LI, Haifeng QIN, Weixia WANG, Lili QU, Juan AN, Hongjun GAO, Xiaoqing LIU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2013-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Epidermal growth factor receptor
Gefitinib
Erlotinib
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2013.07.03

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2013.07.03

Similar Items